EUVIMEDEUVIMED entdecken
Open Access

High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer

Gwan Hee Han, Hee Yun, Joon-Yong Chung, Jae-Hoon Kim, Hanbyoul Cho

Oncology Reports · 2023

DOI: 10.3892/or.2023.8539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, 2023. Verfasst von Gwan Hee Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul 01757, Republic of Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoplasms, Glandular and Epithelial, Vacuolar Proton-Translocating ATPases. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The vacuolar ATPase H+ transporting V1 subunit B1 (ATP6V1B1) belongs to the family of ATP6Vs, which functions to transport hydrogen ions. The expression of ATP6V1B1 and associated clinicopathological features have been linked to various cancers; however, its role in epithelial ovarian cancer (EOC) has remained to be explored. The present study aimed to unveil the function, molecular mechanisms and clinical significance of ATP6V1B1 in EOC. The mRNA levels of ATP6V1 subunits A, B1 and B2 in EOC tissues were determined using data from the Gene Expression Profiling Interactive Analysis database and RNA sequencing. Protein levels of ATP6V1B1 were evaluated through immunohistochemistry staining of EOC, borderline, benign and normal epithelial tissues. The association between ATP6V1B1 expression and clinicopathological features and prognosis of patients with EOC was analyzed. Furthermore, the biological role of ATP6V1B1 in ovarian cancer cell lines was also assessed. RNA sequencing and public dataset analyses revealed elevated ATP6V1B1 mRNA levels in EOCs. High ATP6V1B1 protein levels were also observed in EOC compared with those of borderline and benign tumors and nonadjacent normal epithelial tissues. High ATP6V1B1 expression was associated with the serous cell type, advanced International Federation of Gynecology and Obstetrics stage, high/advanced tumor grade, elevated serum cancer antigen 125 levels and platinum resistance (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsNeoplasms, Glandular and EpithelialVacuolar Proton-Translocating ATPasesHumansFemaleCarcinoma, Ovarian EpithelialBiomarkers, TumorPrognosisRNA, MessengerCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ATP6V1B1biomarkerchemotherapy resistanceepithelial ovarian cancerprognosis

Substanzen

Biomarkers, TumorRNA, MessengerATP6V1B1 protein, humanVacuolar Proton-Translocating ATPases

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul 01757, Republic of Korea.
  • Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06299, Republic of Korea.
  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul 06299, Republic of Korea.

Zitieren

APA

Han, G. H., Yun, H., Chung, J. Y., Kim, J. H., & Cho, H. (2023). High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer. Oncology Reports. https://doi.org/10.3892/or.2023.8539

Vancouver

Han GH, Yun H, Chung JY, Kim JH, Cho H. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer. Oncology Reports. 2023. doi:10.3892/or.2023.8539

BibTeX
@article{Han2023,
  author = {Han, Gwan Hee and Yun, Hee and Chung, Joon-Yong and Kim, Jae-Hoon and Cho, Hanbyoul},
  title = {High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer},
  journal = {Oncology Reports},
  year = {2023},
  doi = {10.3892/or.2023.8539}
}
Kostenlos starten →